Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -19.13% | -12.70% | -10.00% | -16.93% | -2.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.13% | -12.70% | -10.00% | -16.93% | -2.21% |
| Cost of Revenue | -14.59% | -5.09% | -2.39% | -11.47% | 0.81% |
| Gross Profit | -20.44% | -14.92% | -12.11% | -18.46% | -3.05% |
| SG&A Expenses | -5.64% | -1.00% | -2.43% | -18.19% | -16.67% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | 33.38% | 242.25% | 0.62% | 349,000.00% | -- |
| Total Operating Expenses | -18.68% | -0.73% | -11.93% | -18.38% | -17.26% |
| Operating Income | 18.37% | -7.23% | 13.19% | 19.34% | 25.30% |
| Income Before Tax | 16.94% | -7.41% | 9.22% | 34.93% | 14.36% |
| Income Tax Expenses | 169.23% | -1,266.67% | 10.45% | 34.35% | 172.22% |
| Earnings from Continuing Operations | 16.91% | -7.35% | 9.22% | 34.93% | 14.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.91% | -7.35% | 9.22% | 34.93% | 14.32% |
| EBIT | 18.37% | -7.23% | 13.19% | 19.34% | 25.30% |
| EBITDA | 18.83% | -8.16% | 13.15% | 19.89% | 26.03% |
| EPS Basic | 30.35% | 19.15% | 31.52% | 51.04% | 37.62% |
| Normalized Basic EPS | 26.83% | 16.34% | 31.54% | 35.40% | 40.68% |
| EPS Diluted | 30.35% | 19.15% | 31.52% | 51.03% | 37.62% |
| Normalized Diluted EPS | 26.83% | 16.34% | 31.54% | 35.40% | 40.68% |
| Average Basic Shares Outstanding | 19.31% | 32.78% | 32.58% | 32.88% | 37.35% |
| Average Diluted Shares Outstanding | 19.31% | 32.78% | 32.58% | 32.88% | 37.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
